Optimised Tumour Sampling and Processing by a Multidisciplinary Approach for an Accurate Diagnosis in Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Optimised Tumour Sampling and Processing by a Multidisciplinary Approach for an Accurate Diagnosis in Non-Small Cell Lung Cancer

Published:2019-11-12 Issue: Volume: Page:90-99
ISSN:2054-619X
Container-title:EMJ Oncology
language:
Short-container-title:EMJ Oncol

Author:

Rossi Giulio¹,Bargellini Irene²,Bonifazi Martina³,Camplese Pierpaolo⁴,Candoli Piero⁵,Ceron Loris⁶,Gasparini Stefano³,Granone Pier Luigi⁷,Grossi Francesco⁸,Iezzi Roberto⁹,Marchetti Antonio¹⁰,Maur Michela¹¹,Poletti Venerino¹²,Posa Alessandro¹³,Trisolini Rocco¹⁴,Veltri Andrea¹⁵,Zito-Marino Federica¹⁶

Affiliation:

1. Operative Units of Pathology, S. Maria delle Croci Hospital of Ravenna and Degli Infermi Hospital of Rimini, Azienda USL della Romagna, Rimini, Italy

2. Department of Interventional Radiology, Pisa University Hospital, Pisa, Italy

3. Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy; Pulmonary Diseases Unit, Department of Internal Medicine, Azienda Ospedali Riuniti, Ancona, Italy

4. Thoracic Surgery Unit, D’Annunzio University of Chieti-Pescara University Hospital “SS. Annunziata”, Chieti, Italy

5. Pulmonology Unit, Pesaro Fano Hospitals, Azienda Ospedali Riuniti Marche Nord, Pesaro, Italy

6. Pulmonology Unit, Ospedale dell’Angelo, Mestre-Venice, Venice, Italy

7. Department of General Thoracic Surgery, Catholic University, Rome, Italy

8. Division of Medical Oncology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

9. Department of Bioimaging, Institute of Radiology, “A. Gemelli” Hospital, Catholic University of the Sacred Heart, Rome, Italy

10. Center of Predictive Molecular Medicine, CeSI-MeT, University of Chieti-Pescara, Chieti, Italy

11. Division of Medical Oncology, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, Modena, Italy

12. Department of Diseases of the Thorax, Ospedale GB Morgagni, Forlì, Italy; Department of Respiratory Diseases & Allergy, Aarhus University Hospital, Aarhus, Denmark

13. Department of Radiology, S. Giovanni Calibita Fatebenefratelli Hospital, Rome, Italy

14. Interventional Pulmonology Unit, S. Orsola-Malpighi Hospital and Maggiore Hospital, Bologna, Italy

15. Radiology Unit, Department of Oncology. A.O.U. San Luigi Gonzaga, Orbassano (TO), Turin, Italy

16. Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy

Abstract

The classification of lung cancer has evolved parallel to the knowledge of its biomolecular features and is implemented by the analysis of specific gene alterations, which have shown prognostic and predictive values. Consequently, the diagnosis of a specific ‘biomolecular subtype’ of lung cancer is accompanied by different therapeutic strategies. Optimal target tissue sampling plays a key role in the diagnosis and treatment of lung cancer. Tissue samples can be obtained through various techniques involving different healthcare professionals. Therefore, a multidisciplinary approach is crucial to obtain a suitable diagnostic sample encompassing as much of the information as possible for optimal therapeutic management. In this paper, the authors share the expertise of all professionals involved in the diagnostic and therapeutic approaches of patients with lung cancer: pulmonologists, pathologists, oncologists, radiologists, surgeons, and molecular biologists. The different know-how contributions have been gathered in a single text to offer a comprehensive view on the management of the lung cancer tissue journey.

Publisher

European Medical Group

Subject

General Medicine

Reference50 articles.

1. Falconi A et al. Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer. J Thorac Oncol. 2014;9(2):163-9.

2. Loeb LA. Human cancers express mutator phenotypes: Origin, consequences and targeting. Nat Rev Cancer. 2011;11(6):450-7.

3. Maheswaran S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359(4):366-77.

4. Dienstmann R et al. Biomarker-driven patient selection for early clinical trials. Curr Opin Oncol. 2013;25(3):305-12.

5. Rodon J et al. Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol. 2012;9(6):359-66.